Recruiting

Heart imaging scan to detect nerve damage in Parkinson's and Lewy body dementia

Plain-English translation of NCT07176286 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated September 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new imaging agent called that can take detailed pictures of how your heart's nerve system is functioning. Researchers believe this scan may help doctors better diagnose Parkinson's disease and Lewy body dementia, which both damage the nerves that control heart function. The medication is injected into your bloodstream, and then special cameras take images of your heart and body.

In Parkinson's disease and Lewy body dementia, the nerves that control the heart stop working properly, but current imaging methods aren't precise enough to reliably detect this damage. This trial is testing whether this new treatment can provide clearer, more standardized pictures that doctors worldwide could use to confirm these diagnoses.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with Parkinson's disease or Lewy body dementia (for Cohort 1), or with another neurological condition that is not Lewy body disease (for Cohort 2)
your neurological condition has been stable for at least 30 days before enrollment
you are able to lie still on your back for up to 20 minutes during imaging
you are willing and able to follow all study procedures and provide informed consent

You likely don't qualify if…

you have participated in another research study using radiation in the past 12 months that could exceed safe cumulative radiation limits
you have a history of heart disease, prior heart attack, or heart failure
you have kidney problems (serum creatinine greater than 3.0 mg/dL)
you are taking medications that interfere with the imaging agent and cannot safely stop them 24 hours before the scan
you are claustrophobic or have a movement disorder that prevents you from lying still

What participation looks like

You will receive a single intravenous injection of the imaging medication. Thirty minutes after the injection, you will have whole-body imaging scans taken from your head to your pelvis while lying still on a table. A second focused scan of your chest will be taken 60 minutes after the injection. The entire visit should take a few hours, and you will not need to return for additional visits related to this study.

AI-generated summary from trial data · Sep 5, 2026 · Not medical advice

Trial locations(1 site)

United States

Houston Methodist Neurological Institute, Houston, Texas